The usefulness of arylesterase in predicting contrast-induced nephropathy in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention

Abstract

Aim: Oxidative stress is one of the causes of contrast-induced nephropathy (CIN). Paraoxonase1 (PON1), is one of the oxidative stress markers. The most sensitive method that has been in use to measure PON1 enzyme activity is the measurement of arylesterase (AREase) activity. To explore relationship between AREase activity and CIN development. Material and Method: A total of 58 STEMI patients were included in our study. The patients were divided into two groups as CIN (+) and CIN (-). The success of AREase activity level in predicting the development of CIN was also examined by using ROC analysis. Results: Out of the study patients, 13 were CIN (+) and 45 were CIN (-). AREase activity was found to be statistically significantly lower in the CIN (+) group (875 U/L vs 819 U/L, p= 0.004). In the regression analysis, diabetes mellitus, contrast volume and AREase activity were determined as independent risk factors in the development of CIN. As a result of the ROC analysis, we concluded that the AREase activity level <824.1 U/L predicted the development of CIN with 61.5% sensitivity and 86.7% specificity (AUC= 0.768, 95% CI= 0.638-0.868, p=0.001). Conclusion: AREase level is an independent risk factor for the development of CIN and can be used for the prediction of CIN development.

Keywords

• Acute myocardial infarction/STEMI
• angiography
• coronary
• coronary artery disease
• percutaneous coronary Intervention (PCI)
• renal disease
• acute

References

1. Haq MFU, Yip CS, Arora P. The conundrum of contrast-induced acute kidney injury. J Thorac Dis 2020; 12: 1721-7.
2. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med 2019; 380: 2146-55.
3. McCullough PA, Choi JP, Feghali GA, et al. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol 2016; 68: 1465-73.
4. Kusirisin P, Chattipakorn SC, Chattipakorn N. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J Transl Med 2020; 18: 400.
5. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
6. Ako J, Morino Y, Okuizumi K, Usami M, Nakamura M. Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a real-life setting: the final report (J-PLACE Final). Cardiovasc Interv Ther 2016; 31: 101-13.
7. Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-619.
8. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.

9. Akçay AB, Camsarı A, Ozcan T, et al. The relationship between paraoxonase-1 activity and coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars 2011; 39: 371-7.
10. Bhat, M.A., G. Gandhi. Elevated oxidative DNA damage in patients with coronary artery disease and its association with oxidative stress biomarkers. Acta Cardiol 2019; 74: 153-60.
11. Mehran, R., E. Nikolsky. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 100: S11-5.
12. Haagen, L., A. Brock. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992; 30: 391-5.
13. La Du, B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1988; 43: 227-9.
14. Tang WH, Hartiala J, Fan Y, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol 2012; 32: 2803-12.
15. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009; 153: 77-85.
16. Börekçi A, Gür M, Türkoğlu C, et al. Oxidative stress and paraoxonase 1 activity predict contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology 2015; 66: 339-45.
17. Serdar Z, Aslan K, Dirican M, Sarandöl E, Yeşilbursa D, Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem 2006; 39: 794-803.
18. He H, Chen XR, Chen YQ, Niu TS, Liao YM. Prevalence and predictors of contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI): a meta-analysis. J Interv Cardiol 2019; 2019: 2750173.
19. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385: 1397-405.
20. Reddy VS, Bui QT, Jacobs JR, et al. Relationship between serum low-density lipoprotein cholesterol and in-hospital mortality following acute myocardial infarction (the lipid paradox). Am J Cardiol 2015; 115: 557-62.
21. Dong S, Ji W, Zeng S, et al. Admission low-density lipoprotein cholesterol stratified by circulating CD14++CD16+ monocytes and risk for recurrent cardiovascular events following ST elevation myocardial infarction: lipid paradox revised. J Cardiovasc Transl Res 2020; 13: 916-27.
22. Duong MH, MacKenzie TA, Malenka DJ. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv 2005; 64: 471-9.
23. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004; 117: 938-47.
24. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110: 2837-42.
25. Tasanarong A, Vohakiat A, Hutayanon P, Piyayotai D. New strategy of alpha- and gamma-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrol Dial Transplant 2013; 28: 337-44.
26. Farmer, JA. Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2: 208-17.